Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07016802
PHASE1

A Clinical Study of GenSci134 in Healthy Male Adults

Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

View on ClinicalTrials.gov

Summary

To check how safe and well-tolerated a single subcutaneous injection of GenSc134 is in healthy male volunteers

Official title: A Randomized, Double-Blind, Placebo and Positive Drug-Controlled, Single-Dose, Dose-Escalation Phase I Clinical Study of GenSci134 Injection in Healthy Adults

Key Details

Gender

All

Age Range

18 Years - 45 Years

Study Type

INTERVENTIONAL

Enrollment

64

Start Date

2025-06-23

Completion Date

2026-04-13

Last Updated

2025-07-08

Healthy Volunteers

Yes

Interventions

DRUG

GenSci134

only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.

DRUG

GenSci134 Placebo

only one dose of GenSci134 and GenSci134 Placebo to be given, subcutaneous , 7 dose levels will be assigned.

DRUG

Recombinant Human Growth Hormone Injection (Norditropin®)

A single dose of 0.2 mg/day, administered once daily (QD) for 28 consecutive days.

Locations (1)

Peking University Third Hospital

Beijing, Beijing Municipality, China